Sai Parenterals Q2FY27 Results: Operational Margins Expand on Capacity and Portfolio Additions
Sai Parenterals Ltd 路 Press Release 路 01 Nov 2026, 11:48 pm
Sai Parenterals Q2FY27 Results: Operational Margins Expand on Capacity and Portfolio Additions Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196.1 crore, rising 9.0% QoQ, driven by operational efficiencies that expanded gross margin to 47.5%. EBITDA surged 67.4% QoQ to Rs. 41.4 crore with margins at 21.1%, while PAT reached Rs. 10.5 crore despite higher depreciation. H1FY27 revenue stood at Rs. 376.0 crore, tracking at 50% of the full-year Rs. 750 crore target. Unit III expansion completed, boosting monthly capacity by 81% to 155 million units, alongside acquiring 60% stakes in Saicriti Pharma and Sai Prathyak Laboratories.
Original exchange filing (PDF)
More announcements from Sai Parenterals Ltd
- Press Release by Sai Parenteral''s Limited 路 17 Nov 2026
- Outcome of Board Meeting held on Monday, 16th November, 2026 路 17 Nov 2026
- call conducted on Monday the 2nd day of November, 2026. 路 07 Nov 2026
- Audio recording of earning call held on 2nd November, 2026 over call. 路 03 Nov 2026
- Investor Presentation for the quarter and half year ended 30th September, 2026 路 02 Nov 2026
- Statement of variation and deviation for the period ended 30th September, 2026 路 01 Nov 2026
- Financial Results 路 01 Nov 2026
- Sai Parenterals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 01 Nov 2026
